​Vanda Pharmaceuticals, Inc., announced that a Fanapt® patent, number 9,157,121 (‘121 patent), is now listed in the FDA publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. 

The ‘121 patent was issued by the United States Patent and Trademark Office in October 2015 and expires in April 2030. 

Prior to this newly listed patent, the Fanapt® Orange Book listed patents were the U.S. composition of matter patent, the ‘432 patent, the ‘610 patent, the ‘776 patent, the ‘638 patent, the ‘255 patent, the ‘742 patent, the ‘256 patent, and the ‘254 patent, expected to expire in November 2016, September 2025, November 2027, August 2030, October 2030, December 2030, January 2031, February 2031, and December 2031, respectively.